about
Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview projectA small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activityInhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces speciesIn vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolatesHuman immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogsNelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotesStanding genetic variation and the evolution of drug resistance in HIVAggressive chemotherapy and the selection of drug resistant pathogensOxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer CellsMedical management of human immunodeficiency virus infection.An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavirHost sequence motifs shared by HIV predict response to antiretroviral therapyAIDS vaccine development: let a thousand flowers bloom.Computational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors.Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus.Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.Delays in protease inhibitor use in clinical practicePharmacokinetic interaction between ritonavir and indinavir in healthy volunteersAntiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1Perspectives for the treatment of infections with Flaviviridae.Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells.How an inhibitor of the HIV-I protease modulates proteasome activity.Monitoring patients with HIV diseaseHighly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.Long-term patient adherence to antiretroviral therapy.HIV protease inhibitor-related lipodystrophy syndrome.Mechanism of indinavir-induced hyperbilirubinemia.Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsPharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeysSafety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.Urinary NO3 excretion and renal failure in indinavir-treated patients.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisThe drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Antiretroviral therapy adherence among patients living with HIV/AIDS in ThailandAntiretroviral therapy for human immunodeficiency virus infection in 1997.Treatment for human immunodeficiency virus (HIV) infection.Practical issues regarding the use of antiretroviral therapy for HIV infection
P2860
Q24800272-04D3DE04-10B5-4FA1-85BE-7B23B8414C55Q28343321-4B268052-B8D7-4D51-9311-A8EA1A0600C5Q28343602-D87381F2-34DC-4007-B742-715144046577Q28379223-469BF879-DA8C-4687-BD1B-7607E76A0948Q28379226-5DEE7BBF-7816-49C0-B424-0DD97C847677Q28473470-5598750E-466F-4C25-9705-AC2752F27990Q28484153-EA010EFE-161B-401F-91CC-04F51601C379Q28533328-9ACA6AA6-CADE-4D90-B13D-A677983253C4Q28550200-F3FE4572-E5B4-4B38-817F-359109A85BC4Q30371489-637D0A10-712E-42BB-B529-3464ED62239DQ31963272-3CBF13C1-2163-4B0F-9DAC-FE22DE3574C2Q33486144-6005334D-244C-48FC-A992-955A2FA29912Q33534217-B3B755F9-D0DD-442F-AA2A-324A463584FCQ33563075-4C9C33A4-3CF8-41E9-A9CD-787831C9DA95Q33583301-69CA48ED-367E-44D4-B697-CA61839C8669Q33676340-70ADA623-389A-45F7-ABE5-556B07E0CA7FQ33694010-C25ADCF0-8EAE-4771-B0BF-6EFF1570ED07Q33700538-CEE62E75-BF97-4BB5-BF2B-5CE33B5AFCA2Q33700962-402407B4-DAA7-4B06-9473-B0AA6E94651DQ33812419-D10BA209-8D30-4035-89A9-5F3246B0A972Q33821343-F6505689-C264-40FB-B800-AE33059E88BDQ33882609-D62790F1-09B1-43A9-AD23-D92E3342C3F9Q33925492-C9CDF95E-C573-404E-A4DF-598DDD3AE6E1Q33938250-9F632950-FFA2-460C-86E4-45EE0A2742D2Q33941936-EFF940DD-ADDE-434E-BBF2-FAFAFAC24BB2Q33946511-E3EBC5E8-A400-4891-9D20-D5B3C4C740FDQ33946902-F52B42DD-5B90-47BA-8C86-C6F5D84BBB2BQ33947992-59E2D170-BAD5-4B17-8ADB-D2764EF69424Q33975889-022EA04A-0E75-4289-80FB-427AF5AA4C2AQ33976709-6155433D-06AC-42E3-A191-47886C8962A5Q33977160-B41B2C83-44CD-483B-9BE6-9C68063162C8Q33979982-D50D49C4-3FE8-4833-A9B4-9B10087FAF81Q33998505-18FEF50C-5D93-4AD9-A6DC-B83AA7AEE553Q34010283-586022D4-5D2F-4C58-9298-9DC38B45E53DQ34065800-24DC5DE1-9543-4A2F-8E89-1C261C27716AQ34113462-8CF4675A-D222-48BF-AFEF-D2364363F6A3Q34165125-2A20C776-724C-45C7-A24C-7E75ABBC436EQ34185841-345A3806-B719-4EF3-92BF-7E0EDDBFC0FAQ34186823-09513CD6-D3D6-474F-82F3-2EAF7DE85EDCQ34187889-CE38787E-52FD-4988-85F2-DDA0617377F9
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
HIV-1 protease inhibitors. A review for clinicians.
@en
type
label
HIV-1 protease inhibitors. A review for clinicians.
@en
prefLabel
HIV-1 protease inhibitors. A review for clinicians.
@en
P2093
P1476
HIV-1 protease inhibitors. A review for clinicians.
@en
P2093
P304
P356
10.1001/JAMA.1997.03540260059037
P407
P577
1997-01-01T00:00:00Z